Angels for Change Statement Included in Congressional Hearing on Strengthening the U.S. Health Care Supply Chain
Last month, the House Energy & Commerce Health Subcommittee held a critical hearing titled: “Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain.”
Angels for Change submitted a formal statement for the record—bringing the voice of the patient directly to policymakers.
New Legislation Takes Aim at Drug Shortages—Angels for Change Recognized in MAPS Act Launch
Angels for Change is officially recognized in the introduction of the bipartisan Mapping America’s Pharmaceutical Supply (MAPS) Act, a groundbreaking bill introduced by Representatives Doris Matsui (D-CA) and Dan Crenshaw (R-TX). This legislation directly addresses vulnerabilities in the drug supply chain by requiring greater transparency, mapping critical drug components, and identifying potential risks before they impact patient care
Angels for Change Statement Included in Congressional Hearing on Strengthening the U.S. Health Care Supply Chain
Last month, the House Energy & Commerce Health Subcommittee held a critical hearing titled: “Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain.”
Angels for Change submitted a formal statement for the record—bringing the voice of the patient directly to policymakers.
New Legislation Takes Aim at Drug Shortages—Angels for Change Recognized in MAPS Act Launch
Angels for Change is officially recognized in the introduction of the bipartisan Mapping America’s Pharmaceutical Supply (MAPS) Act, a groundbreaking bill introduced by Representatives Doris Matsui (D-CA) and Dan Crenshaw (R-TX). This legislation directly addresses vulnerabilities in the drug supply chain by requiring greater transparency, mapping critical drug components, and identifying potential risks before they impact patient care
The latest edition of The Change Maker Chronicle is here!
We're taking bold steps and sharing real stories as we push the movement to end drug shortages to the NEXT LEVEL.
In this issue, hear directly from Shortage Warriors whose voices are driving change, explore major advocacy milestones, and get a first look at what’s ahead in Q3. From national policy impact to community-powered action, this edition shows what’s possible when Change Makers like you stand with us.
👉 Read the Changemaker Chronicle: Issue 12, Quarter 2, 2025
Together, we’re leveling up the mission—because every patient deserves access to the medicine they need.
At the Oley Foundation, our mission for over four decades has been to support people who rely on parenteral and enteral nutrition (PN and EN). As CEO, I’ve witnessed firsthand how fragile our drug supply chain can be—especially for the medically complex patients who depend on life-sustaining therapies every single day.
Until recently, it felt like we were fighting that battle alone.
That changed two years ago, when I first connected with Laura Bray, founder of Angels for Change. Laura had been working closely with manufacturers, distributors, and government agencies to improve access to sterile, generic injectable medications. While her focus spanned many therapies, one kept surfacing in her data: parenteral nutrition.
A single PN bag can contain 40–70 ingredients, each one sterile, and many sourced as generic injectables—often among the most at-risk for shortage. In hospitals, PN is compounded daily. At home, it’s delivered weekly. Any break in the chain can be catastrophic.
A Shared Purpose
From our first conversation, it was clear: Angels for Change and the Oley Foundation weren’t just aligned in mission—we shared values.
Laura’s patient-centered approach, her respect for lived experience, and her deep dive into shortage data resonated with everything we advocate for at Oley. Together, we committed to changing the narrative from quiet resignation—“you get what you get, so don’t pitch a fit”—to one of action, advocacy, and accountability.
Real-World Collaboration
Over the past two years, our partnership has taken many forms:
Emergency Response: In September 2024, when a hurricane disrupted a major manufacturer’s operations, Angels for Change activated its national network, while Oley mobilized our support lines. Together, we ensured that vulnerable home infusion patients didn’t fall through the cracks.
National Convenings: Laura invited me to speak at several supply chain resilience panels—always making sure the patient voice was part of the conversation. In turn, Oley amplified Angels for Change’s proposals at our forums, giving them the weight of real community experience.
Joint Advocacy: In March 2025, I was proud to join Laura in briefing the Republican Doctor Caucus on Capitol Hill. We spotlighted how drug shortages endanger not just PN patients—but our entire healthcare system.
It’s Personal, Too
This partnership isn’t just strategic—it’s personal. Laura and I check in often, not just to share data or plan advocacy, but to support one another. We celebrate the wins—like securing an emergency line item in a state budget—and we troubleshoot the tough moments, when shortages reappear or policy progress stalls.
In a field where organizations often operate in silos, our collaboration stands out. Two women, leading two nonprofits, with one shared purpose: making sure no patient goes without the therapy they need.
Looking Ahead
Our joint goal remains simple and urgent: A day when every patient—no matter where they live—receives their full, customized therapy exactly when it’s needed.
I’m honored to stand beside Laura Bray and the Angels for Change team in this fight—and deeply grateful for the friendship, trust, and shared determination that powers our work.
— Beth Gore, PhD
Chief Executive Officer
The Oley Foundation
FOR IMMEDIATE RELEASE
Angels for Change Partners with Mark Cuban Cost Plus Drug Company to Combat Oncology Drug Shortages
New Project PROTECT Grant Targets National Supply Gaps in Carboplatin and Methotrexate Injections
TAMPA, FL – June 23, 2025 – In a decisive move to safeguard pediatric cancer patients from life-threatening drug shortages, Angels for Change has awarded a 2025 Project PROTECT grant to a 503B Outsourcing Facility operated by the Mark Cuban Cost Plus Drug Company.
This groundbreaking partnership will fast-track the production of two essential chemotherapy drugs—Carboplatin Injection and Methotrexate Injection—both currently in critical national shortage. By expanding onshore manufacturing and supply readiness, the collaboration aims to ensure timely access to these life-saving medications for patients and healthcare providers across the country during shortage.
This marks the first collaboration between the patient advocacy nonprofit and Mark Cuban Cost Plus Drug Company who share a mission to prevent and mitigate drug shortages.
“Through Project PROTECT, we’re proactively safeguarding patients from drug shortages before they become crises,” said Laura Bray, Founder and Chief Change Maker of Angels for Change. “Partnering with trusted innovators like Mark Cuban Cost Plus ensures that even during supply chain disruptions, patients can access the medications they depend on without delays.”
A Proactive Approach to Prevention
Launched in 2022, Project PROTECT (Proactive Response to Essential Drug Shortages through End-to-End Coordination and Trust) is the only national program that funds pharmaceutical production before shortages reach critical levels. By leveraging predictive data and strategic onshore manufacturing partnerships, the initiative creates a robust safety net for at-risk medications.
The 2025 grant will support targeted infrastructure investments and expanded manufacturing of Carboplatin and Methotrexate—two cornerstone drugs in cancer treatment protocols.
“These medications are essential to cancer care,” said Alex Oshmyansky, Founder & CEO, Mark Cuban Cost Plus Drug Company. “We are proud to work alongside Angels for Change to help ensure they remain available for every patient who needs them.”
Building a Resilient Future for Patient Access
PROTECT represents a new standard in pharmaceutical supply chain resilience—focusing on transparency, early intervention, and patient-first solutions. By anticipating potential shortages and investing in readiness, Angels for Change and Mark Cuban Cost Plus are reshaping how the healthcare system protects access to vital medications.
About Project PROTECT
Project PROTECT is a national initiative that provides grants to 503B Outsourcing Facilities to proactively manufacture essential medications at risk of shortage. Learn more: www.angelsforchange.org/project-protect
About Angels for Change
Angels for Change is a nonprofit patient advocacy organization dedicated to ending drug shortages through advocacy, awareness, and a more resilient pharmaceutical supply chain.
About Mark Cuban Cost Plus Drug Company
The Mark Cuban Cost Plus Drug Company is committed to making medications more affordable and accessible by offering them at transparent, low-cost prices. The company partners directly with manufacturers to help fix the broken pharmaceutical supply chain. Learn more: www.markcubancostplusdrugcompany.com
Angels for Change announces Fagron Sterile Services US (FSS) has been awarded a 2025 Project PROTECT grant to produce sterile water for injection (SWIFI), a critical component in the preparation of injectable medications and currently listed on the FDA’s drug shortage list.
Angels for Change supports the Mapping America’s Pharmaceutical Supply (MAPS) Act introduced May 15th. This bipartisan legislation marks a critical step toward addressing the root causes of drug shortages and promoting transparency, accountability, and resilience in the U.S. pharmaceutical supply chain.
